Titratable sleep apnoea device cleared by FDA
28 September, 2016Oventus Medical has received clearance from the US FDA for the O2Vent T device, an oral appliance intended to alleviate snoring and obstructive sleep apnoea.
Just add water: on-demand pharmaceutical manufacturing
26 September, 2016US researchers have been working on a molecular manufacturing method that can produce a broad range of biomolecules anywhere in the world, without power or refrigeration.
Most innovative biotech company announced
23 September, 2016Swiss biotech company BioLingus has been selected as the 2016 winner of The CEO Magazine's Most Innovative Biotech Company award.
Duchenne muscular dystrophy drug approved by FDA
22 September, 2016The US FDA has announced the approval of a Western Australian-developed drug to treat Duchenne muscular dystrophy (DMD) — a rare and fatal muscle wasting disease affecting one in 3500 boys worldwide.
Making drug development less secretive could lead to quicker, cheaper therapies
15 September, 2016 by Matthew Todd, University of Sydney and Alice Williamson, University of SydneyWith the right investment, an open source drug discovery system — based on sharing all information in the public domain in real time — might compete with the traditional pharmaceutical industry to deliver the drugs we need.
Sartorius Stedim Biotech Connect Upstream bioprocessing platform
11 September, 2016Sartorius Stedim Biotech (SSB) has developed an innovative and fully integrated technology platform to meet the requirements of today's upstream bioprocessing.
PPS to treat viral joint pain and arthritis
08 September, 2016Paradigm Biopharmaceuticals and Griffith University have announced pentosan polysulfate sodium (PPS) as a potential breakthrough in the treatment for alphavirus-induced arthralgia and arthritis.
R&D Tax Incentive cuts proposed
05 September, 2016AusBiotech is not happy with some of the savings measures included in the Omnibus Savings Bill — specifically, the proposed cuts to the Research & Development (R&D) Tax Incentive.
Point-of-care testing for infectious diseases set to rise
05 September, 2016The infectious diseases point-of-care testing (POCT) market is set to rise from $696.1 million in 2015 to just over $1.17 billion by 2022, representing a compound annual growth rate of 7.7%.
Better method of bone regeneration
30 August, 2016Biomedical engineers have used a cheap, commercially produced polymer to assist in bone regeneration, which could result in better therapies for spinal injuries, bone grafts and other orthopaedic surgeries.
New chemical to treat koalas with chlamydia
30 August, 2016Australian scientists have announced a breakthrough in their quest for a new drug to treat koalas suffering from chlamydia.
Cannabis deal completed ahead of human trial
23 August, 2016Australian biotech company Medlab has signed a significant cannabis supply agreement with Aphria, a Canadian-licensed producer of medical marijuana.
Detecting doping with a bacterial enzyme
18 August, 2016ANU researchers are engineering a bacterial enzyme that could help detect many performance-enhancing drugs over longer time frames compared with current anti-doping tests.
MTPConnect and ARCS Australia sign MoU
11 August, 2016MTPConnect and ARCS Australia have signed a memorandum of understanding that will officially recognise ARCS as one of MTPConnect's education affiliates.
Biomedical Translation Fund officially opens
04 August, 2016The federal government's Biomedical Translation Fund has been officially launched by Minister for Health and Aged Care Sussan Ley and Minister for Industry, Innovation and Science Greg Hunt.
